PC
RETA

PA Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

PA Capital’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$10K Buy
+100
New +$12.5K 0.01% 174
2019
Q4 		– Sell
-800
Closed -$64K – 152
2019
Q3 		$64K Buy
+800
New +$67.9K 0.06% 120

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

PA Capital's RETA Position: Q3 2020 in Review

PA Capital increased its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) stake by 44% in Q3 2020, buying an estimated $290K and bringing the position to 7,658 shares worth $746K. The position accounts for 0.52% of the portfolio, ranked #66.

PA Capital first reported a position in RETA in Q4 2018 and has held it in 8 quarters since. The position peaked at $844K in Q1 2019. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

  • PA Capital held 7,658 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $746K as of Q3 2020.
  • PA Capital bought 2,322 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $290K.
  • Reata Pharmaceuticals, Inc. Class A Common Stock made up 0.52% of PA Capital's portfolio in Q3 2020, its #66 holding.
  • PA Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018 and has held it in 8 quarters since.
  • PA Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $844K in Q1 2019.
  • 186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.